Highlights:
- Total potential milestone and upfront payments - $130 million.
- Tiered royalties on sales
- a percentage of sublicensing revenue
- Option to reacquire the rights
Monday, April 30, 2012
Tolero and MannKind Sign Collaboration
Search This Blog
Interviews with management
- Interview with Alfred E. Mann - June-2010
- Al Mann speech at Johns Hopkins - 2010 (new)
- Al Mann speech at OCR - 2010 (new)
- Fox news video on inhaled insulin
- Pete Richardson - Clip syndicate video
- MannKind's CFO Pfeffer Upbeat on Afresa's Future
- Interview with Dr Andrea Leone Bay
- Hakan interview - may 26-2010
MNKD Quick quote
Upcoming events
Subscribe To Afrezza blog
Posts
Comments
Labels
Wells Fargo
(13)
Rodman
(10)
HbA1C
(8)
afrezza
(8)
Bank of America
(7)
Al Mann
(6)
FDA
(5)
Mannkind
(5)
Hapoalim
(4)
Oppenheimer
(4)
Griffin
(3)
JP Morgan
(3)
Leerink
(3)
Renshaw
(3)
Research analyst
(3)
TI
(3)
CRT
(2)
Comparison of Exubera and Afresa
(2)
Diabetologists
(2)
Early intervention
(2)
JMP
(2)
Joshua Schimmer
(2)
Piper Jaffray
(2)
Technosphere
(2)
first phase insulin release
(2)
hypos
(2)
titration
(2)
Approval
(1)
Baird
(1)
Comments
(1)
Cramer
(1)
Guest contributor
(1)
Heinemann
(1)
Morgan Stanley
(1)
PPG
(1)
Pulmonary Delivery
(1)
Real users
(1)
Shorts
(1)
Transcripts
(1)
Valuation
(1)
eAG
(1)
earnings conference call summary
(1)
interview
(1)
Links I like
Yahoo !
Google Mannkind feed
Mannkind's products
